You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The decision is based on data from the Phase II HER2CLIMB trial, which evaluated Tukysa in combination with Herceptin and capecitabine.
Merck and Seattle Genetics will codevelop the antibody drug conjugate ladiratuzumab vedotin, while Merck gains ex-US commercialization rights to the HER2 inhibitor Tukysa.
